Table 1 The P values are resultant from Pearson χ 2 test of association or Fishers Exact when an asterisk is included
Variable | Calpain-9 expression in total patient cohort | Calpain-9 expression in patients that received endocrine therapy | ||||
|---|---|---|---|---|---|---|
Low | High | P value | Low | High | P value | |
Age | ||||||
≤40 years | 36 (4.6%) | 40 (5.1%) | 0.025 | 4 (1.4%) | 2 (0.7%) | 0.695* |
>40 years | 429 (54.8%) | 278 (35.5%) | 160 (54.1%) | 130 (43.9%) | ||
Size | ||||||
≤2 cm | 296 (38.0%) | 166 (21.3%) | 0.001 | 88 (29.7%) | 56 (18.9%) | 0.055 |
>2 cm | 166 (21.3%) | 151 (19.4%) | 76 (25.7%) | 76 (25.7%) | ||
Stage | ||||||
1 | 294 (37.7%) | 168 (21.6%) | 0.009 | 70 (23.6%) | 53 (17.9%) | |
2 | 128 (16.4%) | 115 (14.8%) | 73 (24.7%) | 64 (21.6%) | 0.784 | |
3 | 39 (5.0%) | 35 (4.5%) | 21 (7.1%) | 15 (5.1%) | ||
Grade | ||||||
1 | 87 (11.2%) | 48 (6.2%) | 0.255 | 8 (2.7%) | 8 (2.7%) | 0.498 |
2 | 155 (19.9%) | 101 (13.0%) | 53 (17.9%) | 50 (16.9%) | ||
3 | 220 (28.2%) | 168 (21.6%) | 103 (34.8%) | 74 (25.0%) | ||
Nottingham prognostic index | ||||||
<3.4 | 158 (20.3%) | 71 (9.1%) | 0.002 | 7 (2.4%) | 7 (2.4%) | 0.909 |
3.4-5.4 | 219 (28.2) | 176 (22.7%) | 117 (39.5%) | 94 (31.8%) | ||
>5.4 | 83 (10.7%) | 70 (9.0%) | 40 (13.5%) | 31 (10.5%) | ||
Basal status | ||||||
Non-basal | 351 (46.9%) | 240 (46.9%) | 0.582 | 138 (48.6%) | 104 (36.6%) | 0.257 |
Basal | 90 (12.0%) | 68 (9.1%) | 20 (7.0%) | 22 (7.7%) | ||
ER status | ||||||
Negative | 105 (13.8%) | 97 (12.8%) | 0.014 | 26 (9.0%) | 29 (10.0%) | 0.180 |
Positive | 345 (45.5%) | 212 (27.9%) | 134 (46.4%) | 100 (34.6%) | ||
PgR status | ||||||
Negative | 183 (24.3%) | 138 (18.3%) | 0.246 | 64 (22.6%) | 51 (18.0%) | 0.257 |
Positive | 265 (35.1%) | 168 (22.3%) | 96 (33.9%) | 72 (25.4%) | ||
HER2 status | ||||||
Negative | 394 (51.5%) | 264 (34.5%) | 0.099 | 131 (45.5%) | 111 (38.5%) | 0.765 |
Positive | 55 (7.2%) | 52 (6.8%) | 26 (9.0%) | 20 (6.9%) | ||
Lymphovascular invasion | ||||||
Negative | 255 (36.9%) | 168 (26.1%) | 0.490 | 82 (32.2%) | 76 (29.8%) | 0.164 |
Positive | 127 (19.7%) | 94 (14.6%) | 59 (23.1%) | 38 (14.9%) | ||